Fig. 5

Improved survival of brain tumour bearing SCID mice following combination therapy with temozolomide and irradiated NK92MI-IR cells. (A) Experimental protocol involving GSC1123-initiated brain tumours in SCID mice and therapy with systemic TMZ and intracranial injection of irradiated NK92MI cells (NK92MI-IR). (B-C) Examples of BLI imagery of brain tumour formation and therapeutic response to indicated agents. (D) Kaplan-Meier survival curves of mice bearing GSC1123 tumours and treated with NK92MI-IR cells alone (n = 5, 1 repeat) or combination therapy of TMZ + intracranial NK92MI-IR (n = 8, 2 repeats). These results are overlayed with previously collected GSC1123 survival data, including: untreated mice (n = 13), NK92MI alone (n = 5), TMZ + media (n = 15) and TMZ + NK92MI (n = 8). (E) Kaplan-Meier survival curves for SCID mice with GSC83 intracranial xenografts including: untreated tumour bearing mice (n = 5) and treatments with NK92MI-IR cells (n = 4), TMZ + media (n = 6, 3 repeats) or combination therapy of TMZ + NK92MI-IR (n = 5, 2 repeats) cells. Statistical analysis comparing groups: TMZ + Media vs. TMZ + NK92MI-IR, for both, GSC tumour models, was conducted by curve analysis using the Gehan-Breslow-Wilcoxon test